Plato BioPharma Presenting Preclinical capabilities at PKPD Summit Boston - KPLC 7 News, Lake Charles, Louisiana

Plato BioPharma Presenting Preclinical capabilities at PKPD Summit Boston

  • More Local NewsLocal

  • Tuesday, May 21 2013 9:47 AM EDT2013-05-21 13:47:14 GMT
    We are thrilled to share an update on a Sulphur teen with a rare disease that we introduced you to in March.Brother and sister, Sam and Sydni Dupre, have Friedreich's Ataxia.  This is a disease threatening
    Sam Dupre of Sulphur had the Lake Charles Civic Center crowd on its feet as he moved his wheelchair aside and walked across the stage to receive his diploma.

  • Tuesday, May 21 2013 9:33 AM EDT2013-05-21 13:33:07 GMT
    A four-year-old Bell City boy has just been diagnosed with a deadly disease that is causing him to go backwards in development.  Speaking, chewing, swallowing, seeing and walking were once thoughtless
    Four-year-old Coy Fruge of Bell City has been diagnosed with a deadly disease that is causing him to go backwards in development.  KPLC's Britney Glaser shares his story in this "Faces of Rare Disease."

  • A 42-year-old DeQuincy man is facing dozens of stalking-related charges after officials allege he followed the Glenmora-area victim throughout Rapides Parish.
    A 42-year-old DeQuincy man is facing dozens of stalking-related charges after officials allege he followed the Glenmora-area victim throughout Rapides Parish.
    •   

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Plato BioPharma, Inc.

WESTMINSTER, Colo., March 19, 2013 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) will be presenting their integrated pharmacology capabilities at the "PKPD Summit Boston" in Boston, Massachusetts on March 20, 2013.  The presentation will overview PBI's integrated pharmacology approach.  The presentation will be delivered by Drs. Glenn J. Smits, PhD and Craig F. Plato, PhD, President of Plato BioPharma, Inc.

"Clients trust PBI to deliver complex preclinical proof of concept studies due to our extensive industry experience in disease modeling and discovery pharmacology.  We're participating in the PKPD Summit to detail our broader capabilities and expertise in drug discovery.  We appreciate the challenges of translating preclinical work, and believe PBI is well-positioned to address these challenges and provide disease-relevant PK and PD approaches.  We strive to bring a more creative and partnering approach to the preclinical paradigm to deliver the highest quality science while decreasing the time for enabling decisions thus minimizing cost," said Dr. Plato.

Founded in 2009, Plato BioPharma, Inc. is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution of engagements ranging from pharmacokinetics through disease model development and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.

Contact: Bob Leahy
Phone: 303-506-6960
Email: bleahy@platobiopharma.com
Website: www.platobiopharma.com

©2012 PR Newswire. All Rights Reserved.